Kiniksa PharmaceuticalsKNSA
About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Employees: 297
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
11% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 46
7% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $1.25M
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
13.0% less ownership
Funds ownership: 100.59% [Q1] → 87.59% (-13.0%) [Q2]
16% less funds holding
Funds holding: 154 [Q1] → 130 (-24) [Q2]
17% less capital invested
Capital invested by funds: $793M [Q1] → $659M (-$134M) [Q2]
55% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 44
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Jefferies Roger Song 56% 1-year accuracy 5 / 9 met price target | 50%upside $40 | Buy Initiated | 13 Sept 2024 |
Wedbush David Nierengarten 49% 1-year accuracy 25 / 51 met price target | 27%upside $34 | Outperform Maintained | 23 Jul 2024 |
